---
document_datetime: 2025-09-22 13:47:26
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/romvimza-epar-all-authorised-presentations_en.pdf
document_name: romvimza-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.6501507
conversion_datetime: 2025-12-18 21:00:33.643095
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
| MA (EU) Number                                     | (Invented) name            | Strength          | Pharmaceutical Form         | Route of Administration    | Immediate Packaging                                               | Pack size                        |
|----------------------------------------------------|----------------------------|-------------------|-----------------------------|----------------------------|-------------------------------------------------------------------|----------------------------------|
| EU/1/25/1968/001 EU/1/25/1968/002 EU/1/25/1968/003 | ROMVIMZA ROMVIMZA ROMVIMZA | 14 mg 20 mg 30 mg | Capsule, hard Capsule, hard | Oral use Oral use Oral use | blister (OPA/alu/PVC) blister (OPA/alu/PVC) blister (OPA/alu/PVC) | 8 capsules 8 capsules 8 capsules |